Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,049.98 +27.77 (+0.55%) Dow
38,047.87 +294.56 (+0.78%) Nasdaq
15,756.92 +73.55 (+0.47%) Bitcoin USD
63,846.47 +2,554.99 (+4.17%) CMC Crypto 200
885.54 0.00 (0.00%)
Stoke Therapeutics, Inc. (STOK)
- Business Wire
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BEDFORD, Mass., April 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership te
- Business Wire
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.
- Business Wire
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BEDFORD, Mass., March 28, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730
